TransCode Therapeutics, Inc. (RNAZ) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 4.71M |
| Enterprise Value | -13.1M |
| P/E Ratio | -0.03 |
| PEG Ratio | -0 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 0.01 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | 0.14 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | 0 |
| Operating Margin | 0 |
AD
Management Effectiveness
| Return On Assets | -0.28 |
| Return On Equity | -0.58 |
Income Statement
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -34.31M |
| Net Income | -34.66M |
| Diluted EPS | -52.59 |
Balance Sheet
| Total Cash | 8.38M |
| Total Cash/Share | 8.95 |
| Total Debt | 652,411 |
| Total Debt/Equity | 0 |
| Current Ratio | 1.97 |
| Book Value Per Share | 147.63 |
Price History
| 52-Week Change | -88.43 |
| 52-Week High | 15.94 |
| 52-Week Low | 1.52 |
| Moving Average 50 Days | 2.51 |
| Moving Average 200 Days | 6.61 |
Statistics
| Average Volume | 50,189 |
| Shares Outstanding | 1.06M |
| % Held by Institutions | 3.74 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | -40.33 |
| Last Split Factor | 1:28 |
| Last Split Date | May 15, 2025 |
AD
